• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intraperitoneal nivolumab in a patient with pancreatic cancer and refractory malignant ascites.

作者信息

Wang Sing-Ting, Chiu Chang-Fang, Bai Hui-Jen, Bai Li-Yuan

机构信息

Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, 40402, Taiwan.

Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, 40402, Taiwan; Cancer Center, China Medical University Hospital, Taichung, 40402, Taiwan; College of Medicine, School of Medicine, China Medical University, Taichung, 40402, Taiwan.

出版信息

Eur J Cancer. 2021 May;148:48-50. doi: 10.1016/j.ejca.2021.01.045. Epub 2021 Mar 15.

DOI:10.1016/j.ejca.2021.01.045
PMID:33735808
Abstract
摘要

相似文献

1
Intraperitoneal nivolumab in a patient with pancreatic cancer and refractory malignant ascites.腹腔内注射纳武单抗治疗一名胰腺癌伴难治性恶性腹水患者。
Eur J Cancer. 2021 May;148:48-50. doi: 10.1016/j.ejca.2021.01.045. Epub 2021 Mar 15.
2
Nivolumab activity in advanced refractory malignant peritoneal mesothelioma.纳武单抗在晚期难治性恶性腹膜间皮瘤中的活性。
Eur J Cancer. 2021 Feb;144:386-388. doi: 10.1016/j.ejca.2020.11.024. Epub 2020 Dec 25.
3
Nivolumab for malignant peritoneal mesothelioma.尼伏鲁单抗治疗恶性腹膜间皮瘤。
BMJ Case Rep. 2020 Nov 30;13(11):e237721. doi: 10.1136/bcr-2020-237721.
4
A case of merkel leptomeningeal evolution after complete remission upon anti-PD-1 treatment.1例抗PD-1治疗完全缓解后出现默克尔软脑膜转移的病例。
Eur J Cancer. 2019 May;113:55-57. doi: 10.1016/j.ejca.2019.03.009. Epub 2019 Apr 11.
5
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.纳武利尤单抗作为抗 PD-1 治疗晚期胃癌患者中 hyperprogressive disease 的预测因素。
Gastric Cancer. 2019 Jul;22(4):793-802. doi: 10.1007/s10120-018-00922-8. Epub 2019 Jan 9.
6
Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review.治疗性单克隆抗体在晚期胃癌伴腹膜转移患者腹腔内的分布：病例报告及文献复习。
Cancer Chemother Pharmacol. 2022 Nov;90(5):421-426. doi: 10.1007/s00280-022-04479-3. Epub 2022 Sep 30.
7
A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma.一项局部晚期胰腺癌同步免疫治疗和不可逆电穿孔治疗的 1b 期试验。
Surgery. 2020 Oct;168(4):610-616. doi: 10.1016/j.surg.2020.04.057. Epub 2020 Jul 4.
8
Acinar cell carcinoma of the pancreas successfully treated by en bloc resection and intraperitoneal chemotherapy for peritoneal relapse: a case report of a 15-year survivor.
Pancreas. 2001 Jul;23(1):109-12. doi: 10.1097/00006676-200107000-00016.
9
Amazing result of Nivolumab in a patient with multiple carcinoma.纳武单抗治疗一名多癌患者的惊人效果。
J BUON. 2019 Mar-Apr;24(2):865-867.
10
Effectiveness of Nivolumab on Sarcomatoid Malignant Pleural Mesothelioma With Eosinophilia and Eosinophilic Pleural Effusion.纳武单抗治疗伴嗜酸性粒细胞增多和嗜酸性胸腔积液的肉瘤样恶性胸膜间皮瘤的疗效
J Thorac Oncol. 2019 Nov;14(11):e251-e253. doi: 10.1016/j.jtho.2019.06.007.

引用本文的文献

1
Contemporary Management of Malignant Ascites.恶性腹水的当代管理
J Surg Res. 2025 Mar;307:157-175. doi: 10.1016/j.jss.2025.01.025. Epub 2025 Mar 3.
2
Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series.评估浆细胞样尿路上皮癌的治疗模式及新辅助化疗的作用：来自全国和机构联合系列研究的见解
Cancers (Basel). 2024 Sep 1;16(17):3050. doi: 10.3390/cancers16173050.
3
Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study).
PRaG 方案联合腹腔内注射 PD-1 抑制剂治疗晚期难治性伴有癌性腹水的实体瘤的 I/II 期临床研究（PRaG4.0P 研究）。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241264169. doi: 10.1177/15330338241264169.
4
Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies.胰腺癌中的恶性腹水：病理生理学、诊断、分子特征及治疗策略
Front Oncol. 2023 Mar 16;13:1138759. doi: 10.3389/fonc.2023.1138759. eCollection 2023.